Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI 764532 + Cisplatin + Etoposide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 764532 | BI-764532|BI764532|Obrixtamig | CD3 Antibody 99 DLL3 Antibody 6 | BI 764532 is a bispecific antibody targeting DLL3 and CD3, which may lead to activation of T-cell-mediated immune response against DLL3-expressing tumor cells (J Clin Oncol 41, 2023 (suppl 16; abstr 8502)). | |
Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
Etoposide | Vepesid | EPEG|Eposin|VP-16|VP-16-213 | TOPO2 inhibitor 5 | Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06132113 | Phase I | BI 764532 + Cisplatin + Etoposide BI 764532 + Carboplatin + Etoposide | DAREON-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers | Recruiting | USA | SWE | NLD | FRA | ESP | DEU | BEL | 1 |